Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cellular & Molecular Immunology

• Publication date

  2011-01-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cmi.2010.35PMID 21258360PMCID PMC4003131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The good and evil of complement activation in HIV-1 infection

  2010cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.

  2009cited by this paper
• Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59

  2009cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

  2009cited by this paper
• Update in the management of chronic lymphocytic leukemia

  2009cited by this paper
• CD59 Silencing via Retrovirus-Mediated RNA Interference Enhanced Complement-Mediated Cell Damage in Ovary Cancer

  2009cited by this paper
• Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.

  2009cited by this paper
• Intermedilysin-Receptor Interactions during Assembly of the Pore Complex

  2009cited by this paper
• Development of IGF-IR inhibitors in pediatric sarcomas

  2009cited by this paper
• In vivo Model of Follicular Lymphoma Resistant to Rituximab

  2009cited by this paper
• A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS

  2009cited by this paper
• Is there a role for immunotherapy in osteosarcoma?

  2009cited by this paper
• Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

  2008cited by this paper
• Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin

  2008cited by this paper
• First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

  2008cited by this paper
• Anti‐CD20 monoclonal antibody therapy in multiple myeloma

  2008cited by this paper
• The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

  2008cited by this paper
• Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.

  2007cited by this paper
• Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab

  2007cited by this paper
• Mechanisms of killing by anti-CD20 monoclonal antibodies.

  2007cited by this paper
• In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.

  2007cited by this paper
• ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’

  2007cited by this paper
• Defining the CD59-C9 binding interaction.

  2006cited by this paper
• Minimal Residual Disease in Ovarian Cancer as a Target for Complement‐Mediated mAb Immunotherapy

  2006cited by this paper
• Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy

  2006cited by this paper
• Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.

  2006cited by this paper
• Defining the CD59-C9 Binding Interaction*

  2006cited by this paper
• Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59

  2005cited by this paper
• Cholesterol-Dependent Cytolysins, a Family of Versatile Pore-Forming Toxins

  2005cited by this paper
• Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin

  2004cited by this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cited by this paper
• Mechanism of action and resistance to monoclonal antibody therapy.

  2003cited by this paper
• CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.

  2001cited by this paper
• Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

  2001cited by this paper
• Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.

  2000cited by this paper
• Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

  2000cited by this paper
• The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.

  2000cited by this paper
• Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

  2000cited by this paper
• Immunotherapeutic strategies for the treatment of plasma cell malignancies.

  2000cited by this paper
• Overexpression of protectin (CD59) down‐modulates the susceptibility of human melanoma cells to homologous complement

  2000cited by this paper
• Complement Regulatory Proteins

  1999cited by this paper
• Identity of the Residues Responsible for the Species-restricted Complement Inhibitory Function of Human CD59*

  1998cited by this paper
• Complement‐regulatory proteins in ovarian malignancies

  1997cited by this paper
• Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

  1997cited by this paper
• Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17‐1A

  1997cited by this paper
• Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein, CD59

  1997cited by this paper
• Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.

  1996cited by this paper

• Pro‐ and Anti‐Inflammatory Role of Complement in Cancer

  2025cites this paper
• Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody‐Drug Conjugate

  2025cites this paper
• Complement regulators as novel targets for anti-cancer therapy: A comprehensive review.

  2025cites this paper
• Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharide Krestin (PSK) and Polysaccharopeptide (PSP) Using Inverse Docking

  2024cites this paper
• Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

  2024cites this paper
• CD59: Biological function and its potential for drug target action

  2023cites this paper
• Complement System: An Immunotherapy Target in Colorectal Cancer

  2022cites this paper
• Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

  2022cites this paper
• Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies

  2022cites this paper
• Identification of new therapeutic targets of bone cancers by proteomic strategies

  2022cites this paper
• Macromolecular Protein Complexes III: Structure and Function

  2021cites this paper
• Integrative Bioinformatics Analysis Reveals Possible Targets and Mechanism of Ellipticine in Inhibiting Breast Cancer Stem Cells

  2021cites this paper
• Buffy Coat Immunotranscriptomics for Diagnosis of Malignant Pleural Mesothelioma

  2021cites this paper
• How Structures of Complement Complexes Guide Therapeutic Design.

  2021cites this paper
• How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application

  2020cites this paper
• The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

  2020cites this paper
• Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

  2020cites this paper
• The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy

  2019cites this paper
• iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis

  2019cites this paper
• CD59: a promising target for tumor immunotherapy.

  2018cites this paper
• Identification fine des cellules plasmocytaires normales et tumorales dans la moelle osseuse de patients atteints de myélome multiple en cytométrie en flux

  2017cites this paper
• Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma

  2017cites this paper
• CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

  2017cites this paper
• The dual role of complement in cancer and its implication in anti-tumor therapy.

  2016cites this paper
• Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18

  2016influential citation
• Intracellular antigens as targets for antibody based immunotherapy of malignant diseases

  2015cites this paper
• An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.

  2015cites this paper
• Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival

  2015cites this paper
• Análise do papel do peptídeo antimicrobiano nisina sobre a migração de células de câncer de boca

  2015cites this paper
• Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

  2014cites this paper
• Rapid Degradation of the Complement Regulator, CD59, by a Novel Inhibitor*

  2014influential citation
• Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.

  2014cites this paper
• Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Enhances Rituximab-Induced Death and Chemosensitization in B-Cell Lymphoma

  2013influential citation
• Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence

  2013cites this paper
• Construction of an improved drug delivery system tool with enhanced versatility in cell-targeting.

  2013cites this paper
• Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.

  2013cites this paper
• Investigation of a bacterial pore-forming chimera toxin for application as a novel drug-delivery system tool.

  2012cites this paper
• Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.

  2012cites this paper
• Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis

  2012cites this paper
• Monoclonal antibodies for the treatment of cancer.

  2012cites this paper
• rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

  2011cites this paper
• Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.

  2011cites this paper
• The effects of CD59 gene as a target gene on breast cancer cells.

  2011cites this paper